Navigation Links
Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
Date:10/13/2008

Zero Incidence of Late Stent Thrombosis Reported in CUSTOM I, II, and III

Trials

WASHINGTON and MENLO PARK, Calif., Oct. 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I, II and III clinical trials that reinforces the efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery disease. The CUSTOM clinical trials are prospective studies designed to investigate the safety and efficacy of the Custom NX DES system. The three trials have enrolled 220 patients and represent one of the most challenging patient populations -- those with long and/or multiple lesions -- ever studied in DES trials.

"We are pleased to see favorable outcome trend data continue with the CUSTOM Trials even as we look out as far as two and three years of follow-up in very complex patients," commented Pieter R. Stella, MD, Director, Cardiovascular Research, University Medical Centre Utrecht, The Netherlands, and one of the CUSTOM clinical trial investigators, who presented the data during a DES panel at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. "To date, the incidence of late stent thrombosis in all three CUSTOM trials is zero percent and this is particularly encouraging."

The results presented today include three-year follow-up data from 30 patients studied in CUSTOM I, two-year data from the 100 patients in CUSTOM II and one-year data in 90 patients enrolled in CUSTOM III. Patients enrolled in these trials presented with the smallest reference vessel diameter (RVD) ever in a DES study, and CUSTOM II featured the longest av
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
2. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
3. Netsmart Technologies Customer in Pennsylvania Recognized for Achieving Data Benchmarking Milestones
4. Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area
5. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
6. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
7. Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
10. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
11. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... 2014 According to population studies: “North ... now and 2030." If a population explosion like that ... populous state in the country. , To that end, ... Future of North Carolina Forum on December 16th to ... the necessary infrastructure in place? Enough clean water? And ...
(Date:12/13/2014)... ROCHESTER, N.Y. , Dec. 12, 2014 ... engaged in the discovery and development of ... neurodegenerative diseases, today announced publication of a ... microglia, and inhibits remyelination in neurodegenerative disease" ... journal Neurobiology of Disease*.  The publication highlights ...
(Date:12/12/2014)... 2014 Pittcon is pleased to ... includes over 2,000 technical presentations offered in symposia, ... year’s program covers a wide range of applications ... drug discovery, environmental, food science, fuels/energy, genomics, lab ... The Technical Program begins on Sunday, March ...
Breaking Biology Technology:Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... enrolment in a Phase II clinical trial using ... in patients with advanced head and neck cancers. ... Institute of Cancer Research,and The Royal Marsden NHS ...
... Contract Provides for the Sale of Ready to Drink,Suite of Nutritional ... ... or 142%, BASKING RIDGE, N.J., June 5 Millennium Biotechnologies,Inc., ... announced today that it has entered into an,amendment of it,s November ...
... 5 Crystal Research Associates, LLC,announced today that ... Arana Therapeutics Ltd. (AAH: ASX). The full 56-page ... Arana Therapeutics Ltd. ("Arana" or "the Company") ... treat,inflammatory diseases and cancer. Arana,s business is divided ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 3
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... (March 9, 2009)A new study shows that for those ... you,re young or old: arteriovenous (AV) fistulas remain the ... to provide life-sustaining dialysis. Interventional radiologists found no difference ... "patency" or the openness of AV fistulas or accesses ...
... who ate fish at least once a week displayed higher cognitive ... it less frequently, according to a study of nearly 4,000 teenagers ... Eating fish once a week was enough to increase ... per cent, while eating fish more than once a week increased ...
... 9, 2009 Good eating habits can result when ... the Journal of Nutrition Education and Behavior , ... Minnesota report on one of the first studies to ... diet quality during the transition from early to middle ...
Cached Biology News:For old or young dialysis patients, AV fistulas remain pure gold 2For old or young dialysis patients, AV fistulas remain pure gold 3Teenage boys who eat fish at least once a week achieve higher intelligence scores 2Teenage boys who eat fish at least once a week achieve higher intelligence scores 3Regular family meals result in better eating habits for adolescents 2
... Array CGH Genomic Labeling Systems are a ... of genomic DNA samples for array-based Comparative ... and direct labeling formats, the BioPrime Plus ... flexible solution to your genomic labeling needs. ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
... - Monolayer is a system designed for ... in a serum-free environment. The kit contains a ... been optimized for neural stem cell expansion (Johe, ... Development 10 :3129). Human fibroblast growth factor ...
... DNA Polymerase I from E. ... polymerase. The enzyme also contains ... The 5'?3' exonuclease activity enables ... and gaps in the DNA ...
Biology Products: